Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2020

View Archived Issues

AbbVie conducts phase Ib study of eftozanermin alfa in relapsed or refractory multiple myeloma

Enrollment ongoing in phase II study of HTD-1801 in primary biliary cholangitis

Novel potent PI3Kdelta inhibitors that target two different mechanisms of isoform selectivity

AK-002 reduces GI eosinophils and symptoms in eosinophilic gastritis/duodenitis: phase I results

Regenerative approach shows promise in pediatric heart disease

hAd5-COVID-19 vaccine candidate protects nasal and lung airways in nonhuman primates

Preliminary clinical data for proxalutamide in COVID-19

ProTrans-Repeat meets its primary safety endpoint at 24 months

Leqvio approved in Europe for the treatment of hypercholesterolemia or mixed dyslipidemia

Tychan to initiate phase III study of TY-027 in patients with COVID-19

PureTech initiates phase I study of LYT-200 in metastatic solid tumors

Phase I data presented for CTA-101 in patients with R/R B-cell ALL

TAK-573 shows clinical activity in relapsed/refractory multiple myeloma in first-in-human study

Exploratory study suggests ZYN-002 reduces seizures in children with encephalopathies

Hinova Pharmaceuticals patents new PROTACs

Cadila Healthcare discloses new compounds for tuberculosis

Italian researchers identify new compounds for HBV infection

Boryung Pharmaceutical describes new PI3Kdelta and/or DNA-PK inhibitors

Suzhou Ribo Life Science patents FXI-targeting siRNA

MET no better than EMT for cancer metastases

Amarin reports data on Vascepa in COVID-19 outpatients

Aerpio announces phase II data on razuprotafib in glaucoma

Akari releases long-term data on nomacopan in paroxysmal nocturnal hemoglobinuria

Ultimovacs reports 5-year survival data from phase I trial of UV-1 in metastatic melanoma

Phase III study of ruxolitinib in COVID-19 does not meet primary endpoint

PMD-026 shows safety and initial signs of activity in metastatic breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...